Fusion Biopsy Market Revenue to Attain USD 1,556.54 Mn by 2033

17 Dec 2024

Share :

Table of Content

1. Fusion Biopsy Market Revenue and Trends 2023 to 2033 2. Market Overview 3. Report Highlights of the Fusion Biopsy Market 4. Fusion Biopsy Market Trends 5. Regional Outlook 6. Market News 7. Fusion Biopsy Market Coverage 8. Fusion Biopsy Market Key Players

Fusion Biopsy Market Revenue and Trends 2023 to 2033

The global fusion biopsy market revenue was valued at USD 738.94 million in 2024 and is expected to attain around USD 1,556.54 million by 2033, growing at a CAGR of 8.63% during the forecast period. The demand for the fusion biopsy market is increasing due to the rising incidence of prostate cancer.

Market Overview

The fusion biopsy market is the market that covers diagnosis treatment and surgical procedures in identifying and curing cancer. This advanced diagnostic method gives physicians a complete picture of the desired area by mixing the insights from conventional magnetic resonance imaging and ultrasound imaging. This technology further decreases the chances of adverse results by providing enhanced precision and imaging.

Report Highlights of the Fusion Biopsy Market

• By biopsy route, the transrectal segment led the market in 2023. The dominance of the segment can be linked to increasing the commercial availability of fusion biopsy systems for the transrectal approach.
• By biopsy route, the transperineal fusion biopsy segment is expected to grow at a fast rate in the market over the forecast period. The growth of the segment can be credited to the effectiveness provided by this segment in terms of accuracy.
• By end use, the hospital segment dominated the global market in 2023. The dominance of the segment can be linked to the high purchasing power of the hospitals and associated organizations.
• By end use, the ambulatory care centers segment is anticipated to show the fastest growth in the market during the projected period. The growth of the segment is driven by the growing incidence of prostate cancer.

Fusion Biopsy Market Trends

Technological developments in biopsy devices

The ongoing technological advancements in the fusion biopsy market technology including automated equipment and improved imaging methods fuel the market growth. These innovations enhance diagnostic accuracy, propel efficiency, and lessen procedural pain, which makes biopsy machines more attractive and efficient. In addition, there is an increase in the prevalence of cancer across the globe.

• In April 2023, UC San Diego Health announced to provision of a new minimally invasive prostate cancer biopsy procedure. The procedure, known as a transperineal biopsy, combines 3D MRI fusion-guided technology to identify prostate cancer.

Growing investments by the public and private sector

Public and private organizations are improving the prognosis for men having prostate cancer by investing heavy expenditure in R&D for precise and timely diagnosis. Moreover, government initiatives are anticipated to propel the installation rate of fusion biopsy systems across the globe. Because these techniques can cut the cost of biopsy and treatment of small tumors significantly. Whereas private organizations are focusing on improving the overall quality of medical services.

Growth of image-guided biopsy techniques

Due to their high precision and capability to image in real-time, fusion biopsy market techniques such as CT scan guidance and ultrasound are increasingly gaining traction. As the application of image-guided biopsy techniques in diagnostic accuracy and patient outcomes is expanding which will likely propel market growth further. Also, the integration of AI in biopsy devices can improve their efficiency substantially.

Regional Outlook

North America dominated the fusion biopsy market in 2023. The dominance of the region can be credited to the growing number of cancer cases coupled with the increasing adoption of innovative diagnostic technologies. In North America, the U.S. led the market due to the improved effectiveness and adoption of innovative cancer detection technologies. Also, strong government support and developed healthcare infrastructure can impact market growth further.

Asia Pacific is expected to show the fastest growth in the fusion biopsy market over the studied period. The growth of the region can be attributed to the increasing awareness regarding prostate cancer in the region and the developed healthcare infrastructure in emerging economies such as China, India, and Japan. Furthermore, the growing aging population in countries like Japan and South Korea can have a positive impact on market expansion.

Market News

• In September 2024, Koelis partnered with DeepHealth to use the former's prostate fusion MRI software on the latter's Trinity 3D ultrasound platform. The partnership streamlines the prostate MRI reading process and enables 3D targeted fusion biopsy in prostate cancer.
• In January 2024, Quibim added a new cancer detection ability rostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom.

Fusion Biopsy Market Coverage

Fusion Biopsy Market Key Players

• Eigen
• Koninklijke Philips N.V.
• Hitachi Ltd.
• MedCom
• ESAOTE SPA
• KOELIS
• Focal Healthcare
• BK Medical Holding Company, Inc.
• Exact Imaging
• Biobot Surgical Pte Ltd.
• UC-Care Medical Systems Ltd

Market Segmentation

By Biopsy Route

• Transrectal
• Transperineal

By End Use

• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers

Get this report to explore global market size, share, CAGR and trends, featuring detailed segmental analysis and an insightful competitive landscape overview@ https://www.precedenceresearch.com/checkout/5350

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 804 441 9344